Practical approaches to phase I trial development in order to enable faster go / no-go decisions, reduce cost and speed time to market
With recent drug development failures hitting headlines the pressure is on make those crucial go/no-go decisions as early as possible. Some trials are stumbling at phases II and II, so what can be done to ensure the warning signs are spotted as early as possible?
Phase I clinical trials are a increasingly crucial cog in the drug development process as the bid to prevent late stage failures and, of course, save time and money has spurred innovation in trial design and processes at all levels.
The key to facilitating early go/no-go decisions lies in developing biomarkers, ensuring thorough preclinical data and implementing the right trial design...but how?
Pharma IQ’s 3rd annual Innovation in Phase I Clinical Development meeting is back in Italy! You’ll be heading to the fashion capital of Milan this year to discuss the latest case studies, methodologies and strategies to accelerate proof of concept. Save the dates in your diary and register now – the first 15 tickets are at an exclusive price of €199* for Pharma and bio sponsor companies! You can register here
Exclusive Case Study
One of the latest approaches to reduce attrition rates and save costs is through the magic of Positron Emission Tomography (PET) Imaging! Eugenii (Ilan) A. Rabiner, Head, Clinical Imaging Applications, GSK Clinical Imaging Centre will be providing you with the latest developments in imaging techniques and uses.
Download the brochure here for more information.
New additions to the 2012 programme:
- Streamed sessions to tailor your learning
- More interactive breakout and networking sessions - seize the opportunity to have your say!
- Access to e-networker; set up meetings and interact with your peers prior to the event
- A showcase of imaging techniques to help make go no/go decisions as early as possible
- Back by popular demand! More focus on trial design methodologies to save time and spot problems from the outset
What others are saying:
I learned a lot at this conference-the topics were interesting.Janssen
A good mix of functional areas. For training purposes it has been enlightening.ONO Pharmaceutical UK
Informative, examples from daily practice.Medigene AG
Who you will meet:
Heads and managers of
- Clinical Development
- Clinical Pharmacology
- Clinical Operations
- Clinical Research
- PK/PD
- Exploratory Medicine
- Translational Medicine
- Biomarker Development
*Reduced tickets offered by IQPC are non-transferrable between organisations and only transferrable between individuals within the same organisation where written permission is obtained from IQPC in advance. Reduced tickets are available to Pharma or Biotech Companies only. The offer does not extend to any company whose main or partial business is the provision of products or services of any kind to the aforementioned company type. IQPC reserves the right to revoke or refuse issue of reduced tickets at any time.